Skip to main content

Table 3 Secondary outcomes during the study follow-up period

From: Effect of low-dose tadalafil once daily on glycemic control in patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, placebo-controlled pilot study

 

3 months from baseline

6 months from baseline

Tadalafil (n = 45)

Placebo (n = 23)

P-value*

Tadalafil (n = 45)

Placebo (n = 23)

P-value*

IIEF-5

5.96 ± 5.26

0.78 ± 5.82

0.001

6.56 ± 5.32

2.22 ± 5.73

0.003

IPSS

− 4.34 ± 5.91

− 2.77 ± 6.86

0.330

− 4.38 ± 5.86

− 3.08 ± 7.27

0.428

Waist circumference (cm)

0.544 ± 2.45

0.848 ± 1.73

0.598

0.57 ± 3.61

1.44 ± 2.90

0.322

Body mass index (kg/m2)

0.10 ± 0.63

1.29 ± 5.81

0.176

0.29 ± 1.62

1.05 ± 5.99

0.429

Systolic BP (mmHg)

2.44 ± 16.67

− 2.78 ± 19.33

0.251

− 2.04 ± 18.42

− 3.65 ± 17.36

0.730

Diastolic BP (mmHg)

1.69 ± 10.88

− 0.35 ± 13.73

0.507

− 2.44 ± 12.58

1.61 ± 13.87

0.229

Fasting plasma glucose (mg/dL)

− 1.40 ± 16.42

4.35 ± 22.09

0.230

− 6.40 ± 28.53

5.35 ± 17.77

0.046

Insulin (IU/mL)

− 0.88 ± 9.14

0.75 ± 8.90

0.484

− 0.78 ± 10.27

0.67 ± 10.92

0.592

C-peptide (ng/mL)

− 0.04 ± 0.88

0.21 ± 0.49

0.218

− 0.05 ± 0.99

0.18 ± 0.60

0.306

HOMA-IR

− 0.46 ± 3.26

0.18 ± 2.62

0.418

− 0.51 ± 3.58

0.32 ± 3.32

0.361

Total cholesterol (mg/dL)

   

− 6.47 ± 19.80

1.83 ± 1.67

0.106

Triglyceride (mg/dL)

   

− 12.82 ± 109.27

− 7.13 ± 49.25

0.813

HDL-C (mg/dL)

   

0.24 ± 6.13

1.0 ± 7.65

0.660

LDL-C (mg/dL)

   

− 2.67 ± 14.17

3.87 ± 14.54

0.079

BUN (mg/dL)

   

1.14 ± 5.15

1.79 ± 4.76

0.616

Creatinine (mg/dL)

   

− 0.047 ± 0.206

− 0.065 ± 0.143

0.701

eGFR (mL/min/1.73 m2)

   

4.34 ± 9.76

5.85 ± 10.86

0.564

AST (IU/L)

   

0.27 ± 8.52

2.52 ± 15.49

0.440

ALT (IU/L)

   

− 1.49 ± 12.01

6.17 ± 8.39

0.008

  1. Data are presented as mean ± standard deviation
  2. IIEF, International Index of Erectile Function; IPSS, International Prostate Symptom Score; BP, blood pressure; HOMA-IR, homeostatic model assessment-insulin resistance; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate
  3. *P values were derived using Student’s t-test
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us